GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Efavirenz (Sustiva)

Sustiva

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

NIH adult ARV table: Efavirenz

Product / population
Adults with HIV; product-specific renal recommendations.
Renal measure
CrCl (mL/min), usually Cockcroft-Gault.

NIH dose and renal statement

Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.

Source revision: Not established | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The interacting-drug recommendations are preserved from the historical page and require comparison with current HIV guidance.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/efavirenz/

Usual Dosing (Adults)

Adults: SUSTIVA 600 mg orally once daily with a protease inhibitor and/or NRTIs. Take on an empty stomach, preferably at bedtime. Food increases concentrations and may increase adverse reactions; bedtime dosing can improve nervous-system tolerability. Always combine with other antiretrovirals.

With voriconazole: increase voriconazole maintenance to 400 mg every 12 hours and decrease efavirenz to 300 mg daily using capsules (one 200 mg plus two 50 mg, or six 50 mg capsules). Do not break SUSTIVA tablets.

With rifampin in patients >=50 kg, the source recommends increasing efavirenz to 800 mg daily.

GRPH-efavirenz-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

No adjustments needed.

GRPH-efavirenz-02 · Source section: Renal DosingRenal section finder
Separate professional-source layer

University and professional protocols

Professional

NIH adult ARV table: Efavirenz

Open original reference

Open / share this exact local source

NIH ClinicalInfo HIV guidelines · Adults with HIV; product-specific renal recommendations.

Renal method: CrCl (mL/min), usually Cockcroft-Gault.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

NIH dose and renal statement

Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.

efavirenz:nih-arv-efavirenz-1 · Source locator: Appendix B: Efavirenz row

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-05
Renal-function method
CrCl (mL/min), usually Cockcroft-Gault.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
621555e79c945b07c76709444f24d00fbea134977a115a55f96c581962531034

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/efavirenz/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
efa630de5a018c0f29bf77ad15ec20c5bc4ea5262058439faaf5706cd652064f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report